Trial Profile
A phase II study to evaluate the efficacy, safety, and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Inflammatory breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 23 Jul 2007 Updated status from NCT.
- 20 Dec 2006 Info added from 1060015